Do analysts prefer HIND or XLO?

Vyome currently has a consensus price target of $9.25, indicating a potential upside of 314.80%. Given Vyome's stronger consensus rating and higher possible upside, research analysts clearly believe Vyome is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vyome 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HIND or XLO more profitable?

Xilio Therapeutics has a net margin of -34.06% compared to Vyome's net margin of -3,024.84%. Xilio Therapeutics' return on equity of -71.99% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Vyome -3,024.84% -197.33% -138.14% Xilio Therapeutics -34.06% -71.99% -20.43%

Does the media refer more to HIND or XLO?

In the previous week, Xilio Therapeutics had 2 more articles in the media than Vyome. MarketBeat recorded 3 mentions for Xilio Therapeutics and 1 mentions for Vyome. Xilio Therapeutics' average media sentiment score of 1.25 beat Vyome's score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vyome 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xilio Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend APLM or HIND?

Vyome has a consensus price target of $9.25, suggesting a potential upside of 314.80%. Given Vyome's stronger consensus rating and higher probable upside, analysts plainly believe Vyome is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vyome 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, APLM or HIND?

Vyome has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.25 -$10.94M N/A N/A Vyome $320K 48.92 -$10.26M -$3.37 N/A

Is APLM or HIND more profitable?

Apollomics has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Apollomics' return on equity of 0.00% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Vyome -3,024.84% -197.33% -138.14%

Is INKT or HIND more profitable?

MiNK Therapeutics has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. MiNK Therapeutics' return on equity of 0.00% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -92.37% Vyome -3,024.84% -197.33% -138.14%

Which has stronger valuation and earnings, IMMP or HIND?

Vyome has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.04 -$39.78M N/A N/A Vyome $320K 48.92 -$10.26M -$3.37 N/A

Is IMMP or HIND more profitable?

Prima BioMed has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Prima BioMed's return on equity of 0.00% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Vyome -3,024.84% -197.33% -138.14%

Does the media refer more to IMMP or HIND?

In the previous week, Prima BioMed and Prima BioMed both had 1 articles in the media. Prima BioMed's average media sentiment score of 0.98 beat Vyome's score of 0.00 indicating that Prima BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vyome 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ATYR or HIND?

Vyome has a consensus target price of $9.25, indicating a potential upside of 314.80%. Given Vyome's stronger consensus rating and higher possible upside, analysts plainly believe Vyome is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Vyome 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation and earnings, ATYR or HIND?

Vyome has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio aTyr Pharma $190K 259.94 -$74.12M -$0.62 N/A Vyome $320K 48.92 -$10.26M -$3.37 N/A

Is ATYR or HIND more profitable?

aTyr Pharma has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. aTyr Pharma's return on equity of -95.89% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -95.89% -69.67% Vyome -3,024.84% -197.33% -138.14%

Does the media prefer ATYR or HIND?

In the previous week, aTyr Pharma had 3 more articles in the media than Vyome. MarketBeat recorded 4 mentions for aTyr Pharma and 1 mentions for Vyome. aTyr Pharma's average media sentiment score of 0.50 beat Vyome's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vyome 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Vyome (HIND) Competitors

$2.23 +0.05 (+2.29%)

As of 04:00 PM Eastern

Compare

HIND vs. XLO, APLM, INKT, IMMP, and ATYR

Should you buy Vyome stock or one of its competitors? Vyome's main competitors and comparable companies include Xilio Therapeutics (XLO), Apollomics (APLM), MiNK Therapeutics (INKT), Prima BioMed (IMMP), and aTyr Pharma (ATYR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vyome compare to Xilio Therapeutics?

Vyome (NASDAQ:HIND) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Xilio Therapeutics has a net margin of -34.06% compared to Vyome's net margin of -3,024.84%. Xilio Therapeutics' return on equity of -71.99% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-3,024.84%	-197.33%	-138.14%
Xilio Therapeutics	-34.06%	-71.99%	-20.43%

22.1% of Vyome shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 33.0% of Vyome shares are owned by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Xilio Therapeutics had 2 more articles in the media than Vyome. MarketBeat recorded 3 mentions for Xilio Therapeutics and 1 mentions for Vyome. Xilio Therapeutics' average media sentiment score of 1.25 beat Vyome's score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vyome	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xilio Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vyome has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

Vyome currently has a consensus price target of $9.25, indicating a potential upside of 314.80%. Given Vyome's stronger consensus rating and higher possible upside, research analysts clearly believe Vyome is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Vyome has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	48.92	-$10.26M	-$3.37	N/A
Xilio Therapeutics	$43.77M	1.36	-$35.04M	-$1.64	N/A

Summary

Vyome and Xilio Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Vyome compare to Apollomics?

Apollomics (NASDAQ:APLM) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

In the previous week, Vyome had 1 more articles in the media than Apollomics. MarketBeat recorded 1 mentions for Vyome and 0 mentions for Apollomics. Apollomics' average media sentiment score of 0.00 equaled Vyome'saverage media sentiment score.

Company	Overall Sentiment
Apollomics	Neutral
Vyome	Neutral

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 22.1% of Vyome shares are owned by institutional investors. 33.0% of Vyome shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Apollomics has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Apollomics' return on equity of 0.00% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Vyome	-3,024.84%	-197.33%	-138.14%

Vyome has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.25	-$10.94M	N/A	N/A
Vyome	$320K	48.92	-$10.26M	-$3.37	N/A

Vyome has a consensus price target of $9.25, suggesting a potential upside of 314.80%. Given Vyome's stronger consensus rating and higher probable upside, analysts plainly believe Vyome is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vyome	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Apollomics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Vyome has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Summary

Vyome beats Apollomics on 8 of the 13 factors compared between the two stocks.

How does Vyome compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

MiNK Therapeutics has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. MiNK Therapeutics' return on equity of 0.00% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Vyome	-3,024.84%	-197.33%	-138.14%

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 22.1% of Vyome shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by insiders. Comparatively, 33.0% of Vyome shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vyome has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Vyome	$320K	48.92	-$10.26M	-$3.37	N/A

In the previous week, Vyome had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 1 mentions for Vyome and 0 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.00 equaled Vyome'saverage media sentiment score.

Company	Overall Sentiment
MiNK Therapeutics	Neutral
Vyome	Neutral

MiNK Therapeutics presently has a consensus price target of $35.00, indicating a potential upside of 211.67%. Vyome has a consensus price target of $9.25, indicating a potential upside of 314.80%. Given Vyome's stronger consensus rating and higher probable upside, analysts plainly believe Vyome is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vyome	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

MiNK Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Vyome has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Summary

Vyome beats MiNK Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Vyome compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 22.1% of Vyome shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Comparatively, 33.0% of Vyome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vyome has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.04	-$39.78M	N/A	N/A
Vyome	$320K	48.92	-$10.26M	-$3.37	N/A

In the previous week, Prima BioMed and Prima BioMed both had 1 articles in the media. Prima BioMed's average media sentiment score of 0.98 beat Vyome's score of 0.00 indicating that Prima BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vyome	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prima BioMed has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, Vyome has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Prima BioMed currently has a consensus target price of $5.50, indicating a potential upside of 1,406.44%. Vyome has a consensus target price of $9.25, indicating a potential upside of 314.80%. Given Prima BioMed's higher probable upside, analysts clearly believe Prima BioMed is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vyome	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Prima BioMed has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Prima BioMed's return on equity of 0.00% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Vyome	-3,024.84%	-197.33%	-138.14%

Summary

Prima BioMed beats Vyome on 7 of the 13 factors compared between the two stocks.

How does Vyome compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

aTyr Pharma has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Vyome has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 22.1% of Vyome shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by company insiders. Comparatively, 33.0% of Vyome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vyome has a consensus target price of $9.25, indicating a potential upside of 314.80%. Given Vyome's stronger consensus rating and higher possible upside, analysts plainly believe Vyome is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Vyome	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, aTyr Pharma had 3 more articles in the media than Vyome. MarketBeat recorded 4 mentions for aTyr Pharma and 1 mentions for Vyome. aTyr Pharma's average media sentiment score of 0.50 beat Vyome's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vyome	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

aTyr Pharma has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. aTyr Pharma's return on equity of -95.89% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
Vyome	-3,024.84%	-197.33%	-138.14%

Vyome has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	259.94	-$74.12M	-$0.62	N/A
Vyome	$320K	48.92	-$10.26M	-$3.37	N/A

Summary

aTyr Pharma beats Vyome on 9 of the 17 factors compared between the two stocks.

Get Vyome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HIND vs. The Competition

Export

Metric	Vyome	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.30M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.66	12.66	273.28	25.38
Price / Sales	48.92	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	2.14	16.29	12.89	6.14
Net Income	-$10.26M	-$22.72M	$3.47B	$349.01M
7 Day Performance	1.59%	-1.37%	-0.33%	-1.47%
1 Month Performance	3.24%	11.07%	6.51%	2.47%
1 Year Performance	N/A	53.71%	25.19%	15.84%

Vyome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HIND Vyome	2.3717 of 5 stars	$2.23 +2.3%	$9.25 +314.8%	N/A	$15.30M	$320K	N/A	50	Analyst Forecast
XLO Xilio Therapeutics	0.5437 of 5 stars	$9.05 -0.3%	N/A	-9.8%	$59.75M	$43.77M	N/A	70	News Coverage Positive News Analyst Upgrade
APLM Apollomics	1.5897 of 5 stars	$26.20 -1.1%	N/A	+540.1%	$58.19M	$8.50M	N/A	45	Analyst Downgrade
INKT MiNK Therapeutics	2.179 of 5 stars	$11.79 +3.6%	$35.00 +196.9%	-18.3%	$58.07M	N/A	N/A	30	Gap Down
IMMP Prima BioMed	2.9018 of 5 stars	$0.38 -0.5%	$5.50 +1,347.4%	-76.7%	$56.28M	$6.69M	N/A	2,021	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HIND) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vyome (HIND) Competitors

HIND vs. XLO, APLM, INKT, IMMP, and ATYR

How does Vyome compare to Xilio Therapeutics?

Summary

How does Vyome compare to Apollomics?

Summary

How does Vyome compare to MiNK Therapeutics?

Summary

How does Vyome compare to Prima BioMed?

Summary

How does Vyome compare to aTyr Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIND vs. The Competition

Vyome Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vyome (HIND) Competitors

HIND vs. XLO, APLM, INKT, IMMP, and ATYR

How does Vyome compare to Xilio Therapeutics?

Is HIND or XLO more profitable?

Do institutionals and insiders believe in HIND or XLO?

Does the media refer more to HIND or XLO?

Which has more volatility & risk, HIND or XLO?

Do analysts prefer HIND or XLO?

Which has preferable valuation & earnings, HIND or XLO?

Summary

How does Vyome compare to Apollomics?

Does the media prefer APLM or HIND?

Do insiders and institutionals hold more shares of APLM or HIND?

Is APLM or HIND more profitable?

Which has preferable valuation & earnings, APLM or HIND?

Do analysts recommend APLM or HIND?

Which has more risk & volatility, APLM or HIND?

Summary

How does Vyome compare to MiNK Therapeutics?

Is INKT or HIND more profitable?

Do institutionals & insiders believe in INKT or HIND?

Which has stronger valuation & earnings, INKT or HIND?

Does the media prefer INKT or HIND?

Do analysts prefer INKT or HIND?

Which has more risk & volatility, INKT or HIND?

Summary

How does Vyome compare to Prima BioMed?

Do insiders & institutionals believe in IMMP or HIND?

Which has stronger valuation and earnings, IMMP or HIND?

Does the media refer more to IMMP or HIND?

Which has more risk and volatility, IMMP or HIND?

Do analysts prefer IMMP or HIND?

Is IMMP or HIND more profitable?

Summary

How does Vyome compare to aTyr Pharma?

Which has more volatility and risk, ATYR or HIND?

Do insiders and institutionals believe in ATYR or HIND?

Do analysts prefer ATYR or HIND?

Does the media prefer ATYR or HIND?

Is ATYR or HIND more profitable?

Which has better valuation and earnings, ATYR or HIND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIND vs. The Competition

Vyome Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools